ZANTAC Injection Gets FDA Blessing Despite Chemical Concerns
Published Date: 12/12/2025
Notice
Summary
The FDA has decided that ZANTAC injection (25 mg/mL) hasn’t been pulled from the market because of safety or effectiveness problems. This means generic versions can keep getting approved as long as they meet safety rules, especially about tiny impurities. Patients and drug makers can breathe easy knowing ZANTAC injection stays available under strict quality checks.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 0 costs, 1 mixed.
Generics Can Still Be Approved
The FDA says it will continue to approve abbreviated new drug applications (ANDAs) that refer to ZANTAC (ranitidine HCl) injection, equivalent to 25 mg base/mL, as long as the applicants meet all legal and regulatory requirements. That includes satisfying any applicable acceptable intake limit for nitrosamine impurities before approval is granted.
Existing ANDA Approvals Protected
FDA will not begin procedures to withdraw approval of any approved ANDAs that refer to ZANTAC (ranitidine HCl) injection, EQ 25 mg base/mL. The listed product remains in the Orange Book's Discontinued Drug Product List, but existing ANDA approvals that reference it will not be subject to withdrawal procedures based on safety or effectiveness.
Patient Access to ZANTAC Injection
If you are a patient who needs ZANTAC (ranitidine HCl) injection, equivalent to 25 mg base/mL, the FDA determined the product was not withdrawn for safety or effectiveness reasons so long as it can be made to meet nitrosamine impurity limits. That means the drug can remain available through generic approvals if manufacturers meet those safety limits.
Nitrosamine Limits Required for Approval
FDA's determination is conditional: the drug must be manufactured or formulated in a way that satisfies any applicable acceptable intake limit for nitrosamine impurities before ANDAs can be approved. Applicants must meet those nitrosamine intake limits and other regulatory requirements for approval to proceed.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20503, Determination That Oxandrin (Oxandrolone) Tablets, 2.5 Milligrams and 10 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness; Correction
The FDA fixed a previous announcement about Oxandrin tablets (2.5 mg and 10 mg) being pulled from the market due to safety or effectiveness concerns. This update confirms that not only the original drug but also several generic versions were withdrawn and removed from the official drug list. Patients, doctors, and drug makers should note these changes, which affect availability and prescribing options immediately.
Previous / Next Documents
Previous: 2025-22675, National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Meeting
The National Institute of Arthritis and Musculoskeletal and Skin Diseases is holding a virtual meeting on January 27, 2026, to discuss research updates and review grant applications. Anyone interested can watch the open session online, but the grant review part is private to protect sensitive info. This meeting affects researchers and organizations seeking funding and helps decide which projects get support.
Next: 2025-22677, Request Notice: Use of Foreign-Built Small Passenger Vessel in United States Coastwise Trade, M/V COCONUT MONKEY
The Maritime Administration is checking if the foreign-built small passenger vessel M/V COCONUT MONKEY can be used for U.S. coastwise trade without hurting American boat builders or businesses. They’re asking for public comments by January 12, 2026, to help decide. If approved, this could open doors for new passenger services but won’t cost taxpayers anything right now.